Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

about

Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?

P2860

Q58795662-79A8166D-5C83-4EAA-9DBD-18BF17AF4716

P2860

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

Item

http://www.wikidata.org/entity/Q50043588

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Agalsidase alfa versus agalsid ...... an international cohort study.

@en

Agalsidase alfa versus agalsid ...... an international cohort study.

@nl

type

Item

label

Agalsidase alfa versus agalsid ...... an international cohort study.

@en

Agalsidase alfa versus agalsid ...... an international cohort study.

@nl

prefLabel

Agalsidase alfa versus agalsid ...... an international cohort study.

@en

Agalsidase alfa versus agalsid ...... an international cohort study.

@nl

P1476

Agalsidase alfa versus agalsid ...... an international cohort study

@en

P2093

André B P van Kuilenburg

http://www.w3.org/2001/XMLSchema#string

Aneal Khan

http://www.w3.org/2001/XMLSchema#string

Atul Mehta

http://www.w3.org/2001/XMLSchema#string

Carla E M Hollak

http://www.w3.org/2001/XMLSchema#string

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Daniel G Bichet

http://www.w3.org/2001/XMLSchema#string

Daniel Oder

http://www.w3.org/2001/XMLSchema#string

Derralynn A Hughes

http://www.w3.org/2001/XMLSchema#string

Frédéric M Vaz

http://www.w3.org/2001/XMLSchema#string

Marieke Biegstraaten

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

New equations to estimate GFR in children with CKD

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

P304

351-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JMEDGENET-2017-104863

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maarten Arends

P577

2018-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29437868

http://www.w3.org/2001/XMLSchema#string

P932

5931248

http://www.w3.org/2001/XMLSchema#string

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

about

P2860

P2860

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932